Loading company…
Mebias Discovery is a Philadelphia biotech developing drugs through a membrane protein-NMR platform that targets GPCRs.
Founded in 2015 in Philadelphia, US, Mebias Discovery develops pharmaceuticals through a membrane protein-NMR drug discovery platform that identifies molecules acting on G-protein coupled receptors (GPCRs). Its mu-opioid receptor drug is in Phase 1 clinical studies, and it is also developing Sphingosine 1-phosphate receptor agonists for neuropathic pain and neuroinflammation. The company completed four deals, most recently on October 14, 2019, raising USD 3.5 mn in a venture round co-led by Sprout BioVentures and Viva Biotech (Shanghai) Ltd. Its co-founders are Brett Tounge and Lawrence Kuo.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in